Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

BACKGROUND: The live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine (dNS1-RBD, Pneucolin; Beijing Wantai Biological Pharmacy Enterprise, Beijing, China) confers long-lasting and broad protection in animal models and is, to our knowledge, the first COVID-19 mucosal vaccine to e...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Fengcai, Huang, Shoujie, Liu, Xiaohui, Chen, Qi, Zhuang, Chunlan, Zhao, Hui, Han, Jinle, Jaen, Anjuli May, Do, Thai Hung, Peter, Jonathan Grant, Dorado, Alexander Gonzalez, Tirador, Louie S, Zabat, Gelza Mae A, Villalobos, Ralph Elvi M, Gueco, Gemalyn Pineda, Botha, Lauren Livia Greta, Iglesias Pertuz, Shirley Patricia, Tan, Jiaxiang, Zhu, Kongxin, Quan, Jiali, Lin, Hongyan, Huang, Yue, Jia, Jizong, Chu, Xiafei, Chen, Junyu, Chen, Yixin, Zhang, Tianying, Su, Yingying, Li, Changgui, Ye, Xiangzhong, Wu, Ting, Zhang, Jun, Xia, Ningshao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682370/
https://www.ncbi.nlm.nih.gov/pubmed/37979588
http://dx.doi.org/10.1016/S2213-2600(23)00349-1

Ejemplares similares

Ejemplares similares